- Home
- NAAS vs ANTX Comparison
NAAS vs ANTX Comparison
Compare NAAS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- ANTX
- Stock Information
- Founded
- NAAS 2019
- ANTX 2017
- Country
- NAAS China
- ANTX United States
- Employees
- NAAS N/A
- ANTX N/A
- Industry
- NAAS Other Specialty Stores
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- ANTX Health Care
- Exchange
- NAAS Nasdaq
- ANTX Nasdaq
- Market Cap
- NAAS 40.1M
- ANTX 40.0M
- IPO Year
- NAAS 2017
- ANTX 2022
- Fundamental
- Price
- NAAS $2.03
- ANTX $1.32
- Analyst Decision
- NAAS
- ANTX Hold
- Analyst Count
- NAAS 0
- ANTX 5
- Target Price
- NAAS N/A
- ANTX $3.50
- AVG Volume (30 Days)
- NAAS 181.1K
- ANTX 833.6K
- Earning Date
- NAAS 11-20-2024
- ANTX 11-13-2024
- Dividend Yield
- NAAS N/A
- ANTX N/A
- EPS Growth
- NAAS N/A
- ANTX N/A
- EPS
- NAAS N/A
- ANTX N/A
- Revenue
- NAAS $43,258,393.00
- ANTX N/A
- Revenue This Year
- NAAS $19.53
- ANTX N/A
- Revenue Next Year
- NAAS $151.36
- ANTX N/A
- P/E Ratio
- NAAS N/A
- ANTX N/A
- Revenue Growth
- NAAS 50.34
- ANTX N/A
- 52 Week Low
- NAAS $1.42
- ANTX $0.87
- 52 Week High
- NAAS $40.20
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- NAAS 31.54
- ANTX 50.02
- Support Level
- NAAS $1.98
- ANTX $1.32
- Resistance Level
- NAAS $2.16
- ANTX $1.59
- Average True Range (ATR)
- NAAS 0.22
- ANTX 0.09
- MACD
- NAAS -0.06
- ANTX -0.03
- Stochastic Oscillator
- NAAS 8.10
- ANTX 7.89
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.